ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Keunchil Park
Consultant or Advisory Role - Roche (U)
Chun-Ming Tsai
No relevant relationships to disclose
Myung-ju Ahn
No relevant relationships to disclose
Chong-Jen Yu
Consultant or Advisory Role - AstraZeneca; Pfizer
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Roche; Sanofi
Sang-We Kim
No relevant relationships to disclose
Virote Sriuranpong
Research Funding - Roche
Han Pin Kuo
Research Funding - Roche
Jong-Seok Lee
No relevant relationships to disclose
Jin Hyoung Kang
No relevant relationships to disclose
Meng-Chih Lin
Research Funding - Roche
Sarayut Lucien Geater
No relevant relationships to disclose
Gee-Chen Chang
No relevant relationships to disclose
Kasan Seetalarom
No relevant relationships to disclose
Ping Fai Peter So
No relevant relationships to disclose
Ruay-Sheng Lai
No relevant relationships to disclose
Ashley Chi Kin Cheng
No relevant relationships to disclose
Eun Kyung Cho
No relevant relationships to disclose
Shang-Hung Chen
No relevant relationships to disclose
Te-Chun Hsia
No relevant relationships to disclose
Tony Mok
Employment or Leadership Position - The Chinese University of HongKong
Consultant or Advisory Role - AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Honoraria - AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca